Pentraxin 3 as a biomarker of local inflammatory response to vascular injury in systemic lupus erythematosus

References

• Tsokos, G. C. 2011. Systemic lupus erythematosus. N. Engl. J. Med. 365: 2110–2121
   PubMed Web of Science ®Google Scholar
• D'Cruz, D. 1998. Vasculitis in systemic lupus erythematosus. Lupus. 7: 270–274
   PubMed Web of Science ®Google Scholar
• Pyrpasopoulou, A., S. Chatzimichailidou, and S. Aslanidis. 2012. Vascular disease in systemic lupus erythematosus. Autoimmune Dis. 2012: 876456. doi: 10.1155/2012/876456
   PubMedGoogle Scholar
• Castellano, G., A. Di Vittorio, G. Dalfino, et al. 2010. Pentraxin 3 and complement cascade activation in the failure of arteriovenous fistula. Atherosclerosis. 209: 241–7
   PubMedGoogle Scholar
• Ho, C. Y., C. K. Wong, E. K. Li, et al. 2003. Elevated plasma concentrations of nitric oxide, soluble thrombomodulin and soluble vascular cell adhesion molecule-1 in patients with systemic lupus erythematosus. Rheumatology. 42: 117–122
   PubMedGoogle Scholar
• Reynolds, H. R., J. Buyon, M. Kim, et al. 2010. Association of plasma soluble E-selectin and adiponectin with carotid plaque in patients with systemic lupus erythematosus. Atherosclerosis. 210: 569–574
   PubMed Web of Science ®Google Scholar
• Narshi, C. B., I. P. Giles, and A. Rahman. 2011. The endothelium: an interface between autoimmunity and atherosclerosis in systemic lupus erythematosus? Lupus. 20: 5–13
   PubMed Web of Science ®Google Scholar
• Gustafsson, J., I. Gunnarsson, O. Börjesson, et al. 2009. Predictors of the first cardiovascular event in patients with systemic lupus erythematosus – a prospective cohort study. Arthritis Res. Ther. 11: R186. doi:10.1186/ar2878
   PubMed Web of Science ®Google Scholar
• Olusi, S. O., and S. George. 2011. Prevalence of LDL atherogenic phenotype in patients with systemic lupus erythematosus. Vasc. Health Risk Manag. 7: 75–80
   PubMedGoogle Scholar
• de Leeuw, K., B. Freire, A. J. Smit, et al. 2006. Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus. Lupus. 15: 675–682
   PubMed Web of Science ®Google Scholar
• Inforzato, A., S. Jaillon, F. Moalli, et al. 2011. The long pentraxin PTX3 at the crossroads between innate immunity and tissue remodeling. Tissue Antigens. 77: 271–282
   PubMedGoogle Scholar
• Presta, M., M. Camozzi, G. Salvatori, and M. Rusnati. 2007. Role of the soluble pattern recognition receptor PTX3 in vascular biology. J. Cell. Mol. Med. 4: 723–738
   Google Scholar
• Fazzini, F., G. Peri, A. Doni, et al. 2001. PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum. 44: 2841–2850
   PubMed Web of Science ®Google Scholar
• Nebuloni, M., F. Pasqualini, P. Zerbi, et al. 2011. PTX3 expression in the heart tissues of patients with myocardial infarction and infectious myocarditis. Cardiovasc. Pathol. 20: e27–35. doi:10.1016/j.carpath.2010.02.005
   PubMedGoogle Scholar
• Deban, L., R. C. Russo, M. Sironi, et al. 2010. Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat. Immunol. 11: 328–334
   PubMed Web of Science ®Google Scholar
• Bottazzi, B., A. Bastone, A. Doni, et al. 2006. The long pentraxin PTX3 as a link among innate immunity, inflammation, and female fertility. Leukoc. Biol. 79: 909–912
   PubMed Web of Science ®Google Scholar
• Cieślik, P., and A. Hrycek. 2012. Long pentraxin 3 (PTX3) in the light of its structure, mechanism of action and clinical implications. Autoimmunity. 45: 119–128
   PubMed Web of Science ®Google Scholar
• Mantovani, A., S. Valentino, S. Gentile, et al. 2013. The long pentraxin PTX3: a paradigm for humoral pattern recognition molecules. Ann. N. Y. Acad. Sci. 1285: 1–14
   PubMed Web of Science ®Google Scholar
• Suzuki, S., T. Shishido, A. Funayama, et al. 2013. Long pentraxin PTX3 exacerbates pressure overload–induced left ventricular dysfunction. PLoS One. 8: e53133. doi: 10.1371/journal.pone.0053133
   Google Scholar
• Hollan, I., B. Bottazzi, I. Cuccovillo, et al. 2010. Increased levels of serum pentraxin 3, a novel cardiovascular biomarker, in patients with inflammatory rheumatic disease. Arthrit. Care Res. 62: 378–385
   PubMed Web of Science ®Google Scholar
• Matsui, S., J. Ishii, F. Kitagawa, et al. 2010. Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis. 210: 220–225
   PubMed Web of Science ®Google Scholar
• Uusitalo-Seppälä, R., R. Huttunen, J. Aittoniemi, et al. 2013. Pentraxin 3 (PTX3) is associated with severe sepsis and fatal disease in emergency room patients with suspected infection: a prospective cohort study. PLoS One. 8: e53661. doi: 10.1371/journal.pone.0053661
   PubMed Web of Science ®Google Scholar
• Moalli, F., S. Jaillon, A. Inforzato, et al. 2011. Pathogen recognition by the long pentraxin PTX3. J. Biomed. Biotechnol. 2011: 830421. doi: 10.1155/2011/830421
   Google Scholar
• Kim, J., J. K. Koh, E. Y. Lee, et al. 2009. Serum levels of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) and pentraxin 3 (PTX3) as markers of infection in febrile patients with systemic lupus erythematosus. Clin. Exp. Rheumatol. 27: 773–778
   PubMed Web of Science ®Google Scholar
• Shimada, Y., Y. F. Asanuma, K. Yokota, et al. 2014. Pentraxin 3 is associated with disease activity but not atherosclerosis in patients with systemic lupus erythematosus. Mod. Rheumatol. 24: 78–85
   PubMed Web of Science ®Google Scholar
• Hochberg, M. C. 1997. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum. 40: 1725
   PubMed Web of Science ®Google Scholar
• Kim, M. Y., J. P. Buyon, M. Petri, et al. 1999. Equivalence trials in SLE research: issues to consider. Lupus. 8: 620–626
   PubMed Web of Science ®Google Scholar
• Kume, N., H. Mitsuoka, K. Hayashida, and M. Tanaka. 2011. Pentraxin 3 as a biomarker for acute coronary syndrome: comparison with biomarkers for cardiac damage. J. Cardiol. 58: 38–45
   PubMed Web of Science ®Google Scholar
• Üstündağ, M., M. Orak, C. Güloğlu, et al. 2011. Comparative diagnostic accuracy of serum levels of neutrophil activating peptide-2 and pentraxin-3 versus troponin-I in acute coronary syndrome. Anadolu Kardiyol. Derg. 11: 588–594
   Google Scholar
• Duran, S., I. Duran, F. A. Kaptanagası, et al. 2013. The role of pentraxin 3 as diagnostic value in classification of patients with heart failure. Clin. Biochem. 46: 983–7. doi: 10.1016/j.clinbiochem.2013.04.026
   PubMed Web of Science ®Google Scholar
• Ishihara, T., G. Haraguchi, D. Tezuka, et al. 2013. Diagnosis and assessment of Takayasu arteritis by multiple biomarkers. Circ. J. 77: 477–483
   Google Scholar
• Dagna, L., F. Salvo, M. Tiraboschi, et al. 2011. Pentraxin-3 as a marker of disease activity in Takayasu arteritis. Ann. Intern. Med. 155: 425–433
   PubMed Web of Science ®Google Scholar
• Huttunen, R., M. Hurme, J. Aittoniemi, et al. 2011. High plasma level of long pentraxin 3 (PTX3) is associated with fatal disease in bacteremic patients: a prospective cohort study. PLoS One. 6: e17653. doi: 10.1371/journal.pone.0017653
   PubMed Web of Science ®Google Scholar
• Tamura, Y., T. Ono, M. Kuwana, et al. 2012. Human pentraxin 3 (PTX3) as a novel biomarker for the diagnosis of pulmonary arterial hypertension. PLoS One. 7: e45834. doi:10.1371/journal.pone.0045834
   Google Scholar
• Yoneda, M., T. Uchiyama, S. Kato, et al. 2008. Plasma pentraxin3 is a novel marker for nonalcoholic steatohepatitis (NASH). BMC Gastroenterology. 8: 53. doi:10.1186/1471-230X-8-53
   PubMed Web of Science ®Google Scholar
• Diamandis, E. P., L. Goodglick, C. Planque, and M. D. Thornquist. 2011. Pentraxin-3 is a novel biomarker of lung carcinoma. Clin. Cancer Res. 17: 2395–2399
   Google Scholar
• Tong, M., J. J. Carrero, A. R. Qureshi, et al. 2007. Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clin. J. Am. Soc. Nephrol. 2: 889–897
   PubMed Web of Science ®Google Scholar
• Alles, V. V., B. Bottazzi, G. Peri, et al. 1994. Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. Blood. 84: 3483–3493
   PubMed Web of Science ®Google Scholar
• Ormseth, M. J., L. L. Swift, S. Fazio, et al. 2013. Free fatty acids are associated with metabolic syndrome and insulin resistance but not inflammation in systemic lupus erythematosus. Lupus. 22: 26–33
   Google Scholar
• Mok, C. C., W. L. Poon, J. P. S. Lai, et al. 2010. Metabolic syndrome, endothelial injury, and subclinical atherosclerosis in patients with systemic lupus erythematosus. Scand. J. Rheumatol. 39: 42–49
   PubMed Web of Science ®Google Scholar
• Vaidya, D., M. Szklo, M. Cushman, et al. 2011. Association of endothelial and oxidative stress with metabolic syndrome and subclinical atherosclerosis: multi-ethnic study of atherosclerosis. Eur. J. Clin. Nutr. 65: 818–825
   Google Scholar
• Frijns, C. J. M., R. H. W. M. Derksen, P. G. De Groot, et al. 2001. Lupus anticoagulant and history of thrombosis are not associated with persistent endothelial cell activation in systemic lupus erythematosus. Clin. Exp. Immunol. 125: 149–154
   PubMed Web of Science ®Google Scholar
• Nienhuis, H. L., K. de Leeuw, J. Bijzet, et al. 2010. Small artery elasticity is decreased in patients with systemic lupus erythematosus without increased intima media thickness. Arthritis Res. Ther. 12: R181. doi: 10.1186/ar3145
   Google Scholar
• de Leeuw, K., A. J. Smit, E. de Groot, et al. 2009. Longitudinal study on premature atherosclerosis in patients with systemic lupus erythematosus. Atherosclerosis. 206: 546–550
   PubMed Web of Science ®Google Scholar
• Meroni, P. L., M. O. Borghi, E. Raschi, et al. 2004. Inflammatory response and the endothelium. Thromb. Res. 114: 329–334
   PubMed Web of Science ®Google Scholar
• Gresele, P., R. Migliacci, M. C. Vedovati, et al. 2009. Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function. Thromb. Res. 123: 444–451
   PubMed Web of Science ®Google Scholar
• Spronk, P. E., H. Bootsma, M. G. Huitema, et al. 1994. Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study. Clin. Exp. Immunol. 97: 439–444
   PubMed Web of Science ®Google Scholar
• Howe, H. S., K. O. Kong, B. Y. Thong, et al. 2012. Urine sVCAM-1 and sICAM-1 levels are elevated in lupus nephritis. Int. J. Rheum. Dis. 15: 13–16
   Google Scholar
• Santos, M. J., D. Carmona-Fernandes, H. Canhäo, et al. 2012. Early vascular alterations in SLE and RA patients – a step towards understanding the associated cardiovascular risk. PLoS One. 7: e44668. doi:10.1371/journal.pone.0044668
   Google Scholar
• Ramcharan, K. S., G. Y. H. Lip, P. S. Stonelake, and A. D. Blann. 2011. The endotheliome: a new concept in vascular biology. Thromb. Res. 128: 1–7
   Google Scholar
• de Leeuw, K., J. Blaauw, A. J. Smit, et al. 2008. Vascular responsiveness in the microcirculation of patients with systemic lupus erythematosus is not impaired. Lupus. 17: 1010–1017
   PubMed Web of Science ®Google Scholar